Takeda: Attention Deficit Disorder with Hyperactivity trials

The registry lists 49 Attention Deficit Disorder with Hyperactivity studies with Takeda as lead sponsor. 0 are open to participants now and 31 have results posted.

Phase 1 5Phase 2 8Phase 3 26Phase 4 7No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT04085172Phase 4Results posted
• Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT03327402Phase 1Results posted
• Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)TerminatedNCT03325894Phase 3Results posted
• Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 YearsCompletedNCT03325881Phase 3Results posted
• Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)CompletedNCT03260205Phase 3Results posted
• Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)CompletedNCT02604407Phase 3Results posted
• Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT02466425Phase 3Results posted
• Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity DisorderCompletedNCT02466386Phase 3Results posted
• Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity DisorderCompletedNCT02402166Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.TerminatedNCT02163915Phase 1Results posted
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderCompletedNCT01552915Phase 4Results posted
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderCompletedNCT01552902Phase 4Results posted
• Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in EuropeCompletedNCT01500694Phase 3Results posted
• Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01328756Phase 4Results posted
• Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01244490Phase 3Results posted
• Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to MethylphenidateCompletedNCT01106430Phase 3Results posted
• Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01101022Phase 4Results posted
• Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)CompletedNCT01081145Phase 3Results posted
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HClCompletedNCT01081132Phase 3Results posted
• Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT01010750Phase 1Results posted
• Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)CompletedNCT00997984Phase 3Results posted
• Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity DisorderCompletedNCT00877487Phase 4Results posted
• Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00735371Phase 3Results posted
• Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT00697515Phase 3Results posted
• A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00500149Phase 3Results posted
• Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHDCompletedNCT00500071Phase 4Results posted
• An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00337285Phase 3Results posted
• Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17CompletedNCT00152009Phase 3Results posted
• Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00151996Phase 2Results posted
• Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17CompletedNCT00150618Phase 3Results posted
• Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17CompletedNCT00150592Phase 2Results posted
• Drug Use Study With Intuniv® in European CountriesCompletedNCT05870605
• A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in EnglandCompletedNCT05137704
• A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of LifeCompletedNCT04943796
• Drug Use Study With Intuniv® in AustraliaCompletedNCT04866030
• Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHDCompletedNCT02578030Phase 1
• Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)WithdrawnNCT01274221Phase 3
• The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00928148Phase 2
• ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHDCompletedNCT00557960Phase 3
• NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHDCompletedNCT00557011Phase 2
• Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHDCompletedNCT00556296Phase 3
• A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving SimulatorsWithdrawnNCT00458445Phase 3
• Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT00334880Phase 3
• Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1/2
• Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
• Safety and Efficacy of SPD465 in Adults With ADHDCompletedNCT00202605Phase 2
• Safety of SPD465 in Treating Adults With ADHD.CompletedNCT00152035Phase 3
• Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.CompletedNCT00152022Phase 3
• Efficacy and Safety of SPD465 in Adults With ADHDCompletedNCT00150579Phase 3